Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 10/2012

01-10-2012 | Original paper

Risk factors for colon cancer in 150,912 postmenopausal women

Authors: Arthur Hartz, Tao He, John Jacob Ross

Published in: Cancer Causes & Control | Issue 10/2012

Login to get access

Abstract

Background

Prospective data from the Women’s Health Initiative were analyzed to evaluate more than 800 possible risk factors for an association with colon cancer in postmenopausal women.

Methods

Data included 150,912 postmenopausal women between the ages of 50 and 79. The Cox proportional hazard regression analysis was used to identify risk factors independently associated with the development of colon cancer during a median follow-up time of 8 years.

Results

A total of 1,210 women developed colon cancer and 282 developed rectal cancer. Eleven risk factors were independently associated with an increased risk of colon cancer at the p < 0.001 level. In decreasing order of associated χ2 values, they were age, waist girth (especially for subjects without diabetes), use of hormone therapy at baseline (protective), years smoked, arthritis (protective presumably because of medications used for treatment), relatives with colorectal cancer, lower hematocrit levels, fatigue, diabetes, less use of sleep medication, and cholecystectomy. Of the 11 factors, three were significantly associated with an increased risk of rectal cancer: age, waist, and not taking hormone therapy.

Conclusions

The results provide additional support for the importance of waist girth, hormone therapy, smoking, NSAID use, diabetes, and cholecystectomy as risk factors for colon cancer. Some factors previously identified as influencing risk (exercise and black race) did not have a strong independent association with colon cancer in this analysis.
Literature
1.
Giovannucci E (2002) Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 31:925–943CrossRefPubMed
2.
Marshall JR (2008) Prevention of colorectal cancer: diet, chemoprevention, and lifestyle. Gastroenterol Clin North Am 37:73–82 viCrossRefPubMed
3.
The Women’s Health Initiative Study Group (1998) Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 19:61–109CrossRef
4.
Anderson GL, Manson J, Wallace R et al (2003) Implementation of the Women’s Health Initiative study design. Ann Epidemiol 13:S5–S17CrossRefPubMed
5.
Curb JD, McTiernan A, Heckbert SR et al (2003) Outcomes ascertainment and adjudication methods in the Women’s Health Initiative. Ann Epidemiol 13:S122–S128CrossRefPubMed
6.
Hays J, Hunt JR, Hubbell FA et al (2003) The Women’s Health Initiative recruitment methods and results. Ann Epidemiol 13:S18–S77CrossRefPubMed
7.
8.
Hartz A, Houts P, Arnold S, Bartholomew M, Fischer M (1988) A method of quantify confounding in regression analyses applied to data on diet and CHD incidence. J Clin Epidemiol 41:331–337CrossRefPubMed
9.
Wolf LA, Terry PD, Potter JD, Bostick RM (2007) Do factors related to endogenous and exogenous estrogens modify the relationship between obesity and risk of colorectal adenomas in women? Cancer Epidemiol Biomarkers Prev 16:676–683CrossRefPubMed
10.
Ding EL, Mehta S, Fawzi WW, Giovannucci EL (2008) Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women’s Health Initiative randomized trial. Int J Cancer 122:1690–1694CrossRefPubMed
11.
12.
Freedman AN, Slattery ML, Ballard-Barbash R et al (2009) Colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol 27:686–693CrossRefPubMed
13.
Moore LL, Bradlee ML, Singer MR et al (2004) BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord 28:559–567CrossRefPubMed
14.
Beresford SA, Johnson KC, Ritenbaugh C et al (2006) Low-fat dietary pattern and risk of colorectal cancer: the Women’s Health Initiative randomized controlled dietary modification trial. JAMA 295:643–654CrossRefPubMed
15.
Kabat GC, Shikany JM, Beresford SA et al (2008) Dietary carbohydrate, glycemic index, and glycemic load in relation to colorectal cancer risk in the Women’s Health Initiative. Cancer Causes Control 19:1291–1298CrossRefPubMed
16.
Neuhouser ML, Wassertheil-Smoller S, Thomson C et al (2009) Multivitamin use and risk of cancer and cardiovascular disease in the Women’s Health Initiative cohorts. Arch Intern Med 169:294–304CrossRefPubMed
17.
Paskett ED, Reeves KW, Rohan TE et al (2007) Association between cigarette smoking and colorectal cancer in the Women’s Health Initiative. J Natl Cancer Inst 99:1729–1735CrossRefPubMed
18.
Prentice RL, Pettinger M, Beresford SA et al (2009) Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women’s Health Initiative clinical trial and observational study. Cancer Epidemiol Biomarkers Prev 18:1531–1537CrossRefPubMed
19.
Ritenbaugh C, Stanford JL, Wu L et al (2008) Conjugated equine estrogens and colorectal cancer incidence and survival: the Women’s Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev 17:2609–2618CrossRefPubMed
20.
Hoffmeister M, Raum E, Krtschil A, Chang-Claude J, Brenner H (2009) No evidence for variation in colorectal cancer risk associated with different types of postmenopausal hormone therapy. Clin Pharmacol Ther 86:416–424CrossRefPubMed
21.
Reid FD, Mercer PM, Harrison M, Bates T (1996) Cholecystectomy as a risk factor for colorectal cancer: a meta-analysis. Scand J Gastroenterol 31:160–169CrossRefPubMed
22.
Zhao C, Ge Z, Wang Y, Qian J (2012) Meta-analysis of observational studies on cholecystectomy and the risk of colorectal adenoma. Eur J Gastroenterol Hepatol 24:375–381PubMed
23.
Shao T, Yang YX (2005) Cholecystectomy and the risk of colorectal cancer. Am J Gastroenterol 100:1813–1820CrossRefPubMed
24.
Xu YK, Zhang FL, Feng T, Li J, Wang YH (2009) Meta-analysis on the correlation of cholecystectomy or cholecystolithiasis to risk of colorectal cancer in Chinese population. Chin J Cancer 28:749–755CrossRef
25.
Giovannucci E, Colditz GA, Stampfer MJ (1993) A meta-analysis of cholecystectomy and risk of colorectal cancer. Gastroenterology 105:130–141PubMed
26.
Narisawa T, Magadia NE, Weisburger JH, Wynder EL (1974) Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of N-methyl-N′-nitro-N-nitrosoguanidine in rats. J Natl Cancer Inst 53:1093–1097PubMed
27.
Koga S, Kaibara N, Takeda R (1982) Effect of bile acids on 1,2-dimethylhydrazine-induced colon cancer in rats. Cancer 50:543–547CrossRefPubMed
28.
Todoroki I, Friedman GD, Slattery ML, Potter JD, Samowitz W (1999) Cholecystectomy and the risk of colon cancer. Am J Gastroenterol 94:41–46CrossRefPubMed
29.
Slattery ML, Edwards SL, Ma KN, Friedman GD (2000) Colon cancer screening, lifestyle, and risk of colon cancer. Cancer Causes Control 11:555–563CrossRefPubMed
30.
Winawer SJ, Zauber AG, Ho MN et al (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329:1977–1981CrossRefPubMed
31.
Pischon T, Lahmann PH, Boeing H et al (2006) Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 98:920–931CrossRefPubMed
32.
Akhter M, Inoue M, Kurahashi N, Iwasaki M, Sasazuki S, Tsugane S (2008) Reproductive factors, exogenous female hormone use and colorectal cancer risk: the Japan Public Health Center-based Prospective Study. Eur J Cancer Prev 17:515–524CrossRefPubMed
33.
Martinez ME, Grodstein F, Giovannucci E et al (1997) A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 6:1–5PubMed
34.
Zervoudakis A, Strickler HD, Park Y et al (2011) Reproductive history and risk of colorectal cancer in postmenopausal women. J Natl Cancer Inst 103:826–834CrossRefPubMed
35.
Chute CG, Willett WC, Colditz GA, Stampfer MJ, Rosner B, Speizer FE (1991) A prospective study of reproductive history and exogenous estrogens on the risk of colorectal cancer in women. Epidemiology 2:201–207CrossRefPubMed
36.
Tamakoshi K, Wakai K, Kojima M et al (2004) A prospective study of reproductive and menstrual factors and colon cancer risk in Japanese women: findings from the JACC study. Cancer Sci 95:602–607CrossRefPubMed
37.
Taylor ML, Wells BJ, Smolak MJ (2008) Statins and cancer: a meta-analysis of case–control studies. Eur J Cancer Prev 17:259–268CrossRefPubMed
38.
Poynter JN, Gruber SB, Higgins PD et al (2005) Statins and the risk of colorectal cancer. N Engl J Med 352:2184–2192CrossRefPubMed
39.
Haukka J, Sankila R, Klaukka T et al (2010) Incidence of cancer and statin usage—record linkage study. Int J Cancer 126:279–284CrossRefPubMed
40.
Coogan PF, Smith J, Rosenberg L (2007) Statin use and risk of colorectal cancer. J Natl Cancer Inst 99:32–40CrossRefPubMed
41.
Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556CrossRefPubMed
42.
Rondini EA, Harvey AE, Steibel JP, Hursting SD, Fenton JI (2010) Energy balance modulates colon tumor growth: interactive roles of insulin and estrogen. Mol Carcinog 50:370–382
43.
Delellis Henderson K, Duan L, Sullivan-Halley J et al (2010) Menopausal hormone therapy use and risk of invasive colon cancer: the California Teachers Study. Am J Epidemiol 171:415–425CrossRefPubMed
44.
Metadata
Title
Risk factors for colon cancer in 150,912 postmenopausal women
Authors
Arthur Hartz
Tao He
John Jacob Ross
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 10/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0037-4

Other articles of this Issue 10/2012

Cancer Causes & Control 10/2012 Go to the issue

Original paper

Significant calendar period deviations in testicular germ cell tumors indicate that postnatal exposures are etiologically relevant

Original Paper

Green and black tea intake in relation to prostate cancer risk among Singapore Chinese

Original paper

Gallbladder cancer, a vanishing disease?

Original paper

Lifetime risk for cancer death by sex and smoking status: the lifetime risk pooling project

Original paper

Perineal powder use and risk of endometrial cancer in postmenopausal women

Original paper

The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits